drugset / Trial / NCT01640691

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

NCT01640691 ↗

Phase 1/2 Completed 39 enrolled Adimmune Corporation
NaSingle-groupOpen-labelPrevention

Summary

The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza A (H5N1) in healthy adults.

Timeline

Start
2012-07-10
Primary completion
2013-01-02
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AdimFlu-W (H5N1) Vaccine 0.5 ml Intramuscular

Indications